https://doi.org/10.55788/e4fe61b7
Prof. Daniel Sessler (Cleveland Clinic, OH, USA) presented the multicentre, parallel-group, PROTECT (NCT03111875) trial results, which were simultaneously published in The Lancet [1,2]. The rationale behind the study was that intraoperative hypothermia can contribute to blood loss, infection, and myocardial injury, and the researchers asked whether aggressive intraoperative warming was superior to normothermia in mitigating perioperative complications.
A total of 5,013 participants were randomised to receive either aggressive warming to a target core temperature of 37°C (aggressively warmed arm; n=2,507) or routine thermal management to a target of 35.5°C (routine thermal management arm; n=2,506) during non-cardiac surgery. The primary endpoint of PROTECT was a composite of myocardial injury (troponin elevation, apparently of ischaemic origin), non-fatal cardiac arrest, and all-cause mortality within 30 days of surgery, as assessed in the modified intention-to-treat population.
The results showed that at least 1 of the primary outcome components occurred in 9.9% of participants in the aggressively warmed group and 9.6% in the routine thermal management arm (relative risk 1.04; 95% CI 0.87–1.24; P=0.69). With regard to safety, no significant differences were measured between the arms.
Prof. Sessler concluded that aggressive warming management was not superior to routine thermal management for non-cardiac surgeries.
- Sessler DI, et al. Very Mild Perioperative Hypothermia Versus Aggressive Warming And Myocardial Injury After Non-cardiac Surgery: The PROTECT Trial. Abstract 409–08, ACC 2022, 2–4 April, Washington DC, USA.
- Sessler DI, et al. Lancet 2022; 399(10337):1799-1180.
Copyright ©2022 Medicom Medical Publishers
Posted on
Previous Article
« DIAMOND trial: Patiromer lowers risk of severe hyperkalaemia Next Article
Alirocumab significantly reduces high-risk coronary plaques »
« DIAMOND trial: Patiromer lowers risk of severe hyperkalaemia Next Article
Alirocumab significantly reduces high-risk coronary plaques »
Table of Contents: ACC 2022
Featured articles
Alirocumab significantly reduces high-risk coronary plaques
Highlighted Original Research
POISE-3: Tranexamic acid for non-cardiac surgery
Treating chronic mild hypertension during pregnancy leads to better outcomes
New VOYAGER PAD data: Should patients with both PAD and CKD get rivaroxaban?
Alirocumab significantly reduces high-risk coronary plaques
Aggressive warming during non-cardiac surgery does not improve outcomes
Heart Failure and Cardiomyopathy
DIAMOND trial: Patiromer lowers risk of severe hyperkalaemia
Replacing septal reduction therapy with mavacamten for HCM
Omecamtiv mecarbil does not impact exercise capacity of patients with HFrEF
Symptomatic obstructive hypertrophic cardiomyopathy: long-term mavacamten control
Interventional and Structural Cardiology
COMPLETE revascularisation improves angina-related QoL
Plot twist for negative FAME 3 results: early QoL benefits of PCI
1-year CLASP TR results support tricuspid regurgitation repair
Head-to-head: post-TAVR edoxaban not better than DAPT
Chocolate Touch vs Lutonix catheters
No FLAVOUR difference between FFR and IVUS for PCI guidance
Myocardial Infarction
Low-resource countries benefit from global STEMI initiative
Sodium thiosulfate ineffective at cardiac protection
ICM-guided management did not improve MACE after MI
Prevention
PACIFIC-AF: Low bleeding rates for asundexian in atrial fibrillation
RCT-IVVE trial: Do HF patients benefit from annual flu shots?
TRANSLATE-TIMI 70: Primary endpoint met but safety concerns for vupanorsen
Lipoprotein(a) slashed by 98% in APOLLO trial
Dietary intervention from your supermarket
Related Articles
June 15, 2022
Head-to-head: post-TAVR edoxaban not better than DAPT
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com